中国医学前沿杂志（电子版）2023，Vol.15Issue(12)：12-18,7.DOI:10.12037/YXQY.2023.12-03
《非奈利酮在糖尿病合并慢性肾脏病患者中应用的中国专家共识(2023版)》解读
Interpretation of Chinese expert consensus on the use of finerenone in patients with diabetes mellitus and chronic kidney disease(2023 edition)
潘琦 1郭立新1
作者信息
- 1. 北京医院 内分泌科 国家老年医学中心 中国医学科学院老年医学研究院,北京 100730
- 折叠
摘要
Abstract
Diabetic nephropathy is one of the important chronic complications in diabetic patients.Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist(ns-MRA).Fenelidone has been shown to be promising in diabetes mellitus combined with chronic kidney disease.Recently,Interpretation of Chinese expert consensus on the use of finerenone in patients with diabetes mellitus and chronic kidney disease(2023 edition)was released and 27 recommendations were formed focusing on the mechanism of action and pharmacological properties of finerenone,evidence-based medical evidence,appropriate population,specific usage,combined administration and precautions,etc.Herein,the key points of the consensus were expounded in this article to help to improve the clinical practice of diabetic patients with chronic kidney disease.关键词
糖尿病/慢性肾脏病/非奈利酮/专家共识/解读Key words
Diabetes mellitus/Chronic kidney disease/Finerenone/Expert consensus/Interpretation引用本文复制引用
潘琦,郭立新..《非奈利酮在糖尿病合并慢性肾脏病患者中应用的中国专家共识(2023版)》解读[J].中国医学前沿杂志（电子版）,2023,15(12):12-18,7.
